Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Followed by Tiselizumab and R-CHOP in Bulky Follicular Lymphoma
NCT06704555Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in follicular lymphoma (FL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Dec 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06704555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704555.